Chronic lymphocytic leukemia (CLL) remains the most common leukemia of adults and is incurable. Several novel therapies have substantially altered the treatment landscape for CLL, and studying the mechanisms of their activity, toxicity and resistance is of great interest. Our lab focuses on CLL, somatic and germline genomics of CLL and the mechanisms of these targeted therapies in CLL. This position will focus on the PI3K inhibitor drug class as it has poorly understood immunomodulatory effects as well as cell autonomous survival effects. The focus of this position will be the characterization of the immunomodulatory effects of PI3K inhibitors, including several next generation drugs believed to be differentiated from the first generation drug idelalisib, as well as understanding mechanisms of resistance to PI3K inhibitors.
Located in Boston and the surrounding communities, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
The PI3k fellowship will focus on the analysis of correlative samples from patients treated with PI3K inhibitors on novel schedules or combinations designed to manage toxicity or overcome resistance. This analysis will include flow cytometry, CYTOF, TCR sequencing and potentially scRNA sequencing. Additionally we will be analyzing pharmacodynamic endpoints to demonstrate target inhibition in the patient samples. The ideal candidate will be able to perform their own bioinformatics analyses of genomic data. Validation of key findings at the bench will also be required. The ideal candidate will have familiarity and experience working with molecular genetics/genomics, molecular biology, flow cytometry, cell culture and bioinformatics.
Previous experience in molecular biology, cell biology, flow cytometry and informatics is required. These positions will both include high-throughput genomic analyses and require good computational skills and familiarity with bioinformatics. MD, PhD or MD/PhD is required.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.